TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11806300

Group type: EXPERIMENTAL
Intervention: β‐blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium channel agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitors of platelet aggregation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypolipemic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamins C, E and B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics against intra‐cellular germs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Substitutive hormonotherapy of post‐menopausal women
Number of subjects: 0
Study: 9923567

Group type: EXPERIMENTAL
Intervention: Oral etoposide (50 mg/m2 daily for 21 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Optimal sampling strategy (1, 4, and 24 h after administration)
Number of subjects: 32
Study: 7994805

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Combination therapy (Streptokinase and TPA)
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Accelerated TPA
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Flow grade 0 or 1
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Flow grade 2
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Flow grade 3
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Overall early deaths
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Overall later deaths
Number of subjects: 41021
Study: 3181102

Group type: EXPERIMENTAL
Intervention: Lupines
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 30 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 60 mg
Number of subjects: 35
Study: 29437621

Group type: EXPERIMENTAL
Intervention: Murepavadin (single ascending dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Murepavadin (multiple ascending doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (single ascending dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (multiple ascending doses)
Number of subjects: 60
Study: 28659213

Group type: COMPARATOR
Intervention: Usual health messages (UHM)
Number of subjects: 3186

Group type: EXPERIMENTAL
Intervention: Breast-feeding counselling (BFC)
Number of subjects: 3186
Study: 26377496

Group type: EXPERIMENTAL
Intervention: Usual transplant patient education plus ten additional weekly 30‐min education/counseling sessions about immunosuppressive drugs and behavioral changes
Number of subjects: 111
Study: 23221401

Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21792296

Group type: EXPERIMENTAL
Intervention: Subcutaneous ACTH gel 80 U/day for five days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intramuscular ACTH gel 80 U/day for five days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intramuscular ACTH gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous ACTH gel
Number of subjects: 20
Study: 18055864

Group type: EXPERIMENTAL
Intervention: Decitabine (100 mg/m² per course every 4 weeks)
Number of subjects: 3
Study: 17065887

Group type: EXPERIMENTAL
Intervention: Xenon anesthesia (1 minimum alveolar concentration)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (propofol only)
Number of subjects: 12
Study: 14586800

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10487558

Group type: EXPERIMENTAL
Intervention: Biperiden during radiotherapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pilocarpine during radiotherapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no xerostomy prevention therapy)
Number of subjects: 69
Study: 8533995

Group type: EXPERIMENTAL
Intervention: Mesalamine 0.8 g/d
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Mesalamine 1.6 g/d
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Mesalamine 0.8 g/d (intention-to-treat)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Mesalamine 1.6 g/d (intention-to-treat)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo (intention-to-treat)
Number of subjects: 264
Study: 2265735

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 371741

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 30877658

Group type: EXPERIMENTAL
Intervention: 6α‐methylprednisolone acetate (MA) 40 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: triamcinolone acetonide (TA) 40 mg
Number of subjects: 40
Study: 28760939

Group type: EXPERIMENTAL
Intervention: Intensive treatment (<120 mm Hg)
Number of subjects: 7879

Group type: COMPARATOR
Intervention: Standard treatment (<140 mm Hg)
Number of subjects: 7879

Group type: EXPERIMENTAL
Intervention: Highest quintile of OBPV
Number of subjects: 7879

Group type: COMPARATOR
Intervention: Lowest quintile of OBPV
Number of subjects: 7879
Study: 26142514

Group type: EXPERIMENTAL
Intervention: Total flavonoids from Lavandula angustifolia (LTF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25131073

Group type: EXPERIMENTAL
Intervention: ALEM (30 mg intraoperatively)
Number of subjects: 46

Group type: COMPARATOR
Intervention: rATG (multiple doses starting intraoperatively)
Number of subjects: 46
Study: 23006997

Group type: EXPERIMENTAL
Intervention: Multifaceted approach including audit and feedback, educational outreach visits, and patient-mediated interventions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Multifaceted approach
Number of subjects: 32
Study: 20817153

Group type: EXPERIMENTAL
Intervention: CBT + DCS (25 or 50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CBT + Placebo
Number of subjects: 30
Study: 17928622

Group type: EXPERIMENTAL
Intervention: DynaMITE training environment with controlled motorized target movements
Number of subjects: 15
Study: 15494612

Group type: EXPERIMENTAL
Intervention: Omental adipose tissue 20alpha‐HSD mRNA abundance
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Omental adipose tissue 3alpha‐HSD‐3 mRNA abundance
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Omental and subcutaneous adipose tissue 3alpha‐HSD activities
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Omental 20alpha‐HSD mRNA level
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Omental 3alpha‐HSD‐3 mRNA level
Number of subjects: 14
Study: 11875724

Group type: EXPERIMENTAL
Intervention: UICC clinical stage II
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: UICC clinical stage III
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Eosinophilic infiltration (numerous eosinophils)
Number of subjects: 324
Study: 9505188

Group type: EXPERIMENTAL
Intervention: ceftibuten 400 mg once daily
Number of subjects: 309

Group type: COMPARATOR
Intervention: clarithromycin 500 mg twice daily
Number of subjects: 309
Study: 7621455

Group type: EXPERIMENTAL
Intervention: Neoadjuvant combination therapy with flutamide and an LHRH agonist for 3 months
Number of subjects: 161

Group type: COMPARATOR
Intervention: Radical prostatectomy alone
Number of subjects: 161
Study: 3275673

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate/heparin sodium
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 30923970

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided single-puncture arthrocentesis using modified double-lumen single-barrel needle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-puncture arthrocentesis with modified double-lumen single-barrel needle
Number of subjects: 20
Study: 28524257

Group type: EXPERIMENTAL
Intervention: 30-week oral language intervention programme
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: 20-week oral language intervention programme
Number of subjects: 394

Group type: COMPARATOR
Intervention: Untreated waiting control group
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Both intervention programmes
Number of subjects: 394
Study: 26488675

Group type: EXPERIMENTAL
Intervention: Fast-switching strategy (within 1 week)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Slow-switching strategy (within 4 weeks)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both fast and slow switching groups
Number of subjects: 79
Study: 24320906

Group type: EXPERIMENTAL
Intervention: Herbal dentifrice (Hi Ora K, The Himalaya Drug Company)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo dentifrice (The Himalaya Drug Company)
Number of subjects: 73
Study: 21128151

Group type: EXPERIMENTAL
Intervention: General practitioner (GP) engagement in discussing lifestyle behaviors (smoking, alcohol, nutrition)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Patient characteristics (gender and age)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Age as a predictor
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: GP-initiated discussions
Number of subjects: 1029
Study: 17963740

Group type: EXPERIMENTAL
Intervention: Hierarchical sequences training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surface distinctions and counting/repetition detection strategies
Number of subjects: 0
Study: 20199402

Group type: EXPERIMENTAL
Intervention: WG (bathing with wash gel)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: C (bathing and cream)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: WG + C (bathing with wash gel plus cream)
Number of subjects: 64

Group type: COMPARATOR
Intervention: B (bathing with water)
Number of subjects: 64
Study: 15639176

Group type: EXPERIMENTAL
Intervention: OCD patients (n=18)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients (n=16)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Major depressive disorder patients (n=not specified)
Number of subjects: 34
Study: 11277374

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg per day for up to 9 days in a reducing schedule)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 14
Study: 9973793

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (group A)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (group B)
Number of subjects: 113
Study: 7603075

Group type: EXPERIMENTAL
Intervention: Amlodipine (11 mg intravenous dose)
Number of subjects: 13
Study: 3349554

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.012 mg.kg‐1 followed by edrophonium 0.8 mg.kg‐1 with a 1 min priming interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.012 mg.kg‐1 followed by edrophonium 0.8 mg.kg‐1 with a 2 min priming interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.012 mg.kg‐1 followed by edrophonium 0.8 mg.kg‐1 with a 3 min priming interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 followed by neostigmine 0.048 mg.kg‐1 with a 1 min priming interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 followed by neostigmine 0.048 mg.kg‐1 with a 2 min priming interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 followed by neostigmine 0.048 mg.kg‐1 with a 3 min priming interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Equipotent mixtures of antagonists administered as a single bolus dose
Number of subjects: 72
Study: 31731609

Group type: EXPERIMENTAL
Intervention: Guidance group (well‐structured and monitored nutrition and lifestyle counseling for six months)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Guidance group
Number of subjects: 160

Group type: COMPARATOR
Intervention: GA group (one‐time general advice about lifestyle modification)
Number of subjects: 160
Study: 29155973

Group type: EXPERIMENTAL
Intervention: Tapering MTX (double-blind)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Stable MTX (double-blind)
Number of subjects: 427
Study: 26702013

Group type: EXPERIMENTAL
Intervention: Longer skis with reduced width and standing height
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ski-snow friction force (FF)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ski-snow friction coefficient (CoeffF)
Number of subjects: 2
Study: 24292879

Group type: EXPERIMENTAL
Intervention: Nap condition (two 15-min naps)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No-nap condition (no naps taken)
Number of subjects: 15
Study: 22824474

Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 21 days
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 6 months
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 21 days or 6 months
Number of subjects: 306
Study: 20640949

Group type: EXPERIMENTAL
Intervention: Telephonic psycho-social support, leaflet, and adherence diary intervention
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group received only the leaflet
Number of subjects: 279
Study: 16980349

Group type: EXPERIMENTAL
Intervention: Exercise training group (TR; n = 43)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Untrained group (UTR; n = 39)
Number of subjects: 82
Study: 15559609

Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: EVAP
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TUVRP
Number of subjects: 96
Study: 11135382

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PME)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 58
Study: 9554801

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg orally daily for 2 weeks
Number of subjects: 20
Study: 7999487

Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 150
Study: 3243932

Group type: EXPERIMENTAL
Intervention: Suprofen with food (standard meal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Suprofen with milk (8-ounce glass)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Suprofen in fasted state
Number of subjects: 24
Study: 30104006

Group type: EXPERIMENTAL
Intervention: CTRT (RT + weekly cisplatin), n = 94
Number of subjects: 180

Group type: COMPARATOR
Intervention: RT alone, n = 86
Number of subjects: 180
Study: 26632091

Group type: EXPERIMENTAL
Intervention: IPX066 (carbidopa-levodopa extended-release capsules)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 25634565

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (2 mg/kg loading dose, 1 mg/kg/d continuous infusion on days 1‐7, tapered on days 8‐14)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 24231627

Group type: EXPERIMENTAL
Intervention: Cetuximab plus pemetrexed (400 mg/m2 at first dose and 250 mg/m2 weekly thereafter)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Pemetrexed alone (500 mg/m2)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) with cetuximab
Number of subjects: 938

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2) alone
Number of subjects: 938
Study: 20928842

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 250
Study: 18509620

Group type: EXPERIMENTAL
Intervention: Benfotiamine supplementation
Number of subjects: 0
Study: 16980115

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (coronary angiography and revascularisation within 7 days from admission)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Non-invasive primarily medical strategy
Number of subjects: 2457
Study: 12614088

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement among diabetic participants
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo among diabetic participants
Number of subjects: 130
Study: 10472515

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8857325

Group type: EXPERIMENTAL
Intervention: Serum eosinophil peroxidase (S-EPO)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Serum eosinophil cationic protein (S-ECP)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Blood eosinophil count (B-Eos)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Asthma symptom score
Number of subjects: 154
Study: 1764940

Group type: EXPERIMENTAL
Intervention: Insertion of NORPLANT implants with scalpel
Number of subjects: 843

Group type: COMPARATOR
Intervention: Insertion of NORPLANT implants without scalpel
Number of subjects: 843
Study: 6804654

Group type: EXPERIMENTAL
Intervention: Opsite catheter dressings
Number of subjects: 261

Group type: COMPARATOR
Intervention: Standard gauze/tape dressings
Number of subjects: 261
Study: 31539328

Group type: COMPARATOR
Intervention: Single Tourniquet (ST)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Double Tourniquet (DT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-attending inserters
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Attending inserters
Number of subjects: 100
Study: 27913306

Group type: EXPERIMENTAL
Intervention: Icatibant 30 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 27252756

Group type: EXPERIMENTAL
Intervention: Freeze dried Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum and Bifidobacterium lactis (Group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Freeze dried lactic acid bacillus (Group B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo powder (Group C)
Number of subjects: 33
Study: 25298016

Group type: COMPARATOR
Intervention: Nutrition psychoeducation (NPC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MIC)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 89
Study: 22118062

Group type: EXPERIMENTAL
Intervention: PEER intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: CHILD intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both PEER and CHILD interventions
Number of subjects: 60
Study: 19542866

Group type: EXPERIMENTAL
Intervention: ABC/3TC 600 mg/300 mg with lopinavir/ritonavir 800 mg/200 mg
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: TDF/FTC 300 mg/200 mg with lopinavir/ritonavir 800 mg/200 mg
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: ABC/3TC
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 688
Study: 17305685

Group type: EXPERIMENTAL
Intervention: First impression assessment based on pain drawing (PD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Final assessment based on clinical examination
Number of subjects: 50
Study: 15147545

Group type: EXPERIMENTAL
Intervention: Androgen deprivation (leuprolide and chlormadinone acetate) for 3 months followed by radical prostatectomy and subsequent adjuvant endocrine therapy (leuprolide alone)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Surgery followed by 3-month androgen deprivation (leuprolide and chlormadinone acetate) and subsequent adjuvant endocrine therapy (leuprolide alone)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Preoperative androgen deprivation
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Preoperative androgen deprivation in subpopulation with PSA < 35.6 ng/mL and clinical stage B or C cancers
Number of subjects: 176
Study: 11120904

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (1 mg/kg/day for three months, then 10 mg/day for three months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10092565

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment (n = 56)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Reassured following angiography
Number of subjects: 133

Group type: COMPARATOR
Intervention: Reassured without angiography
Number of subjects: 133
Study: 8527061

Group type: EXPERIMENTAL
Intervention: Self-representation scores in middle-aged adults
Number of subjects: 149

Group type: COMPARATOR
Intervention: Self-representation scores in preadolescents and older adults
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Cognitive and personality variables
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Age segments (younger vs older)
Number of subjects: 149
Study: 2180866

Group type: EXPERIMENTAL
Intervention: 67.2 Gy
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 72.0 Gy
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 76.8 Gy
Number of subjects: 237
Study: 7407516

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate while not smoking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate while smoking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate and propranolol (380 mg/day) while not smoking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate and propranolol while smoking
Number of subjects: 10
Study: 29148144

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1645
Study: 27456328

Group type: EXPERIMENTAL
Intervention: Complex intervention involving GPs and HCAs conducting checklist-based interviews and medication reconciliation with the aid of a CDSS.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 100
Study: 25250737

Group type: EXPERIMENTAL
Intervention: Complicated grief treatment (CGT) - 16 sessions delivered approximately weekly (n=74)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Grief-focused interpersonal psychotherapy (IPT) - 16 sessions delivered approximately weekly (n=77)
Number of subjects: 151